Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1002014

CC(C)Oc1ccc(NC(=O)c2cccc(S(=O)(=O)N3CCN4CCCCC4C3)c2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
GAA P10253 3/20 0.51
LMNA P02545 1/20 0.51
MAPK1 P28482 1/20 0.51
TRPV4 Q9HBA0 2/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 1/20 0.47
NPC1 O15118 2/20 0.47
TDP1 Q9NUW8 1/20 0.46
RAB9A P51151 1/20 0.45
CNR1 P21554 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1000490 0.98 MEN1 (0.51) KMT2AMEN1GAALMNAMAPK1
SCHEMBL1002016 0.80 MEN1 (0.40) KMT2AMEN1GAALMNAALDH1A1
SCHEMBL1001582 0.80 KMT2A (0.80) KMT2AMEN1GAALMNAMAPK1
Trifluoroacetic Acid SCHEMBL1000750 0.80 SMN1; SMN2 (0.50) KMT2AMEN1GAALMNAMAPK1
Trifluoroacetic Acid SCHEMBL1000772 0.79 KMT2A (0.48) KMT2AMEN1GAALMNAMAPK1
SCHEMBL1000747 0.79 KMT2A (0.64) KMT2AMEN1GAALMNAMAPK1
Trifluoroacetic Acid SCHEMBL1000613 0.79 ELOVL6 (0.49) KMT2AMEN1GAALMNAMAPK1
SCHEMBL1000673 0.78 KMT2A (0.63) KMT2AMEN1GAALMNAMAPK1
Trifluoroacetic Acid SCHEMBL1003877 0.77 MEN1 (0.46) KMT2AMEN1GAALMNAMAPK1
SCHEMBL1000491 0.77 MEN1 (0.42) KMT2AMEN1LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 KMT2A 473/4885MEN1 4600/4885GAA 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.